IOL Chemicals and Pharmaceuticals Limited (IOLCP), a leading manufacturer of pharmaceutical (APIs) and specialty chemicals reported Q3 FY23 a decline in total income of 6% at Rs. 530 crore vis-a-vis Rs. 564 crore YoY. 

 

EBITDA at Rs. 50 crore as compared to Rs. 37 crore QoQ and Rs. 68 crore YoY. Net profit of the company at Rs 24.15 crore against Rs. 15.67 crore QoQ and Rs. 40.07 crore YoY. 

 

The company completed Paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins. 

 

Commenting on the quarterly performance, Dr. Sanjay Chaturvedi, Executive Director & CEO said, “The quarterly performance reflects our commitment to control our costs and improve our margin trajectory. For the third quarter, EBITDA and net profit margins – both have improved sequentially. Apart from cost rationalisation, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with backward integration of Para Amino Phenol (PAP) and we expect this capacity enhancement to boost volume growth from next quarter onwards.”

 

IOLCP is one of the leading pharmaceutical (APIs) companies and is a significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like - Pain management, anticonvulsants, antidiabetes, anti-cholesterol and anti-platelets.

 

The company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, and Acetyl Chloride.

 

The company is the world's largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facilities. The company has DSIR approved R&D which is fully equipped to validate existing processes.